News | May 26, 2025
Gland Pharma Q4 FY25 PAT falls to Rs. 186.5 Cr
R&D spend for Q4 was Rs. 50.3 crore, 4.9 per cent of Q4?revenue
R&D spend for Q4 was Rs. 50.3 crore, 4.9 per cent of Q4?revenue
This Product is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension
The company expects to launch this product through its marketing partner in the near future
The observations issued are neither repeated observations nor related to data integrity
Our Q3 FY25 revenue was at Rs. 1,384.1 crore with an EBITDA of Rs. 360 crore resulting in a 26% EBITDA margin
Morepen Laboratories approves hiving off of medical devices business
This product is indicated in coagulation disorders caused by vitamin K deficiency or interference with vitamin K activity.
The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Xalatan
The company has reported total income of Rs. 1,465.49 crores during the period ended September 30, 2024
Giri is currently the President (India Business & Emerging Markets) of Amneal Pharmaceuticals
Subscribe To Our Newsletter & Stay Updated
